Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
April 12, 2018
Aeglea BioTherapeutics Presents New Phase 1/2 Trial Data Demonstrating Clinically Relevant Treatment Effects in Arginase 1 Deficiency Patients at the 2018 ACMG Annual Clinical Genetics Meeting
AUSTIN, Texas, April 12, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for ...
April 12, 2018
Paratek Pharmaceuticals Presenting New Data from Omadacycline Development Program at ECCMID 2018
BOSTON, April 12, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (PRTK) announced today that data from its omadacycline clinical and microbiology programs will be presented ...
April 12, 2018
Catalyst Biosciences Announces Korean Ministry of Food and Drug Safety Approves Addition of Sixth Cohort to the Phase 1/2 Trial of CB 2679d/ISU304 in Individuals with Hemophilia B
SOUTH SAN FRANCISCO, Calif., April 12, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address ...
April 12, 2018
Arena Pharmaceuticals Announces Phase 2 Data Presentation for Ralinepag in Pulmonary Arterial Hypertension at the International Society for Heart and Lung Transplantation Annual Meeting
SAN DIEGO, April 12, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced that data from a post-hoc analysis of the 22-week Phase 2 clinical study ...
April 12, 2018
PolarityTE Announces Pricing of Public Offering of Common Stock
SALT LAKE CITY, April 12, 2018 (GLOBE NEWSWIRE) -- PolarityTE, Inc. (COOL), a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of ...
April 11, 2018
PolarityTE Announces Public Offering of Common Stock
SALT LAKE CITY, April 11, 2018 (GLOBE NEWSWIRE) -- PolarityTE, Inc. (COOL), a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of ...
April 11, 2018
Reata Provides Update on the Phase 2 Portion of the CARDINAL Study of Bardoxolone Methyl in Patients With Alport Syndrome
IRVING, Texas, April 11, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (RETA) (Reata or Company), a clinical-stage biopharmaceutical company, today provided an update on the ...
April 11, 2018
Neovasc Announces Receipt of US$7.1 Million from Exercise of Series C Warrants
VANCOUVER , April 11, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter ...
April 11, 2018
BrainStorm Cell Therapeutics to Present at ARM's 6th Annual Cell & Gene Therapy Investor Day, April 17 in New York
NEW YORK and PETACH TIKVAH, Israel, April 11, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative ...
April 11, 2018
TherapeuticsMD Enters Into Label Negotiations for TX-004HR
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (TXMD), an innovative women’s healthcare company, today announced that the Company has entered into negotiations with the U.S. Food and ...
April 11, 2018
Arrowhead Pharmaceuticals Presents ARC-520 Clinical Data at The International Liver Congress™
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (ARWR) today announced the presentation of clinical data on ARC-520, the company’s prior generation investigational medicine for the treatment of ...
April 11, 2018
CymaBay Announces Positive New 12-Week and 26-Week Results from its Ongoing Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis at The International Liver Congress™ 2018
NEWARK, Calif., April 11, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), today announced that a late-breaking poster presentation describing new data from a second ...
April 11, 2018
Zealand and Roche Diabetes Care enter Phase 3 study collaboration for treatment of congenital hyperinsulinism with dasiglucagon
Copenhagen, Denmark, April 11, 2018 - Zealand Pharma ("Zealand") reports that it has engaged in a collaboration with Roche Diabetes Care, a global leader in ...
April 11, 2018
Zogenix to Participate in LEERINK Partners CNS Day
EMERYVILLE, Calif., April 11, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) ...
April 11, 2018
Intec Pharma Announces Pricing of $35.4 Million Public Offering of Ordinary Shares
JERUSALEM, April 11, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced the pricing of an underwritten public offering of 6.75 million of ...
April 11, 2018
Keryx Biopharmaceuticals Receives 2018 Corporate Innovator Award from the National Kidney Foundation
AUSTIN, Texas, April 11, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, ...
April 10, 2018
Onxeo to Present Corporate Overview at the H.C. Wainwright Annual Global Life Sciences Conference
PARIS--(BUSINESS WIRE)--Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company specializing in the development of innovative drugs in oncology, in particular against ...
April 10, 2018
MannKind Announces Completion of Previously Announced $28.0 Million Registered Direct Offering
WESTLAKE VILLAGE, Calif., April 09, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) today announced the completion of its previously announced registered direct offering of 14,000,000 ...
April 10, 2018
ProQR Appoints ADAR Expert Dr. Peter A. Beal to Scientific Advisory Board to Focus on Axiomer® RNA A-to-I Editing Technology
LEIDEN, the Netherlands, April 10, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA ...
April 10, 2018
VBL Therapeutics to Present Late-Breaking Research at the American Association for Cancer Research (AACR) 2018 Annual Meeting on April 16
TEL AVIV, Israel, April 10, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class ...
Page 50 of 117